

1645

Atty Dkt No. 087102-0272558

Pat. App. Ser. No. 10/071,174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: PATENT APPLICATION OF

Reed, et al.

Group Art Unit: 1645

Appln. No.: 10/071,174

Examiner: to be assigned

Filed: February 7, 2002

Title: APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME

TRANSMITTAL LETTER

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached is being Mailed to Addressee by service of the United States Postal Service addressed to Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-1450

Date: March 4, 2004 By:


Sachiko Y. Snedden

Sir:

Transmitted herewith for filing are the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Copy of International Search Report mailed January 21, 2004;
4. Cited References (4); and
5. Return Postcard.

No fee is believed to be incurred for filing this Inquiry. However, the Commissioner is hereby authorized to charge any fee that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 50-2212. A duplicate of this Transmittal is enclosed.


Respectfully submitted,

Pillsbury Winthrop LLP

Date: March 4, 2004

11682 El Camino Real, Suite 200
San Diego, CA 92130-2092
(619) 234-5000

By:


Robert M. Bedgood, Ph.D.
Reg. No. 43,488
Tel. No. (858) 509-4065
Fax No. (858) 509-4010



Atty Dkt No. 087102-0272558
Pat. App. Ser. No. 10/071,174

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Reed, et al.

Group Art Unit: 1645

Serial No.: 10/071,174

Examiner: to be assigned

Filed: February 7, 2002

Title:
APOPTOSIS MODULATOR BCL-B AND
METHODS FOR MAKING AND USING
SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that each enclosed document listed on the herewith Form PTO-1449 was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months ago by the attached PCT Communication (☒ Search Report ☐ Office Action) dated January 21, 2004. See that communication for information on each document.

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached is being Mailed to Addressee by service of the United States Postal Service addressed to Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-1450

By: Sachiko Y. Snedden
Sachiko Y. Snedden

Date: March 4, 2004

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.


Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

No fee is believed to be incurred for filing this statement. However, the Commissioner is hereby authorized to charge any fee, including any submitted herewith, if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account 50-2212, under Order No. 087102-0272558.

Respectfully submitted,

Pillsbury Winthrop LLP


By


Robert M. Bedgood, Ph.D.
Reg. No. 43,488

Date: March 4, 2004

11682 El Camino Real
Suite 200
San Diego, CA 92130-2092
(619) 234-5000

Tel. No. (858) 509-4065
Fax No. (858) 509-4010



Atty.	
Dkt. No.	

M#

Client Ref.

087102-0272558

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Inventor(s): Reed, et al.

Appln. No.: 10/071,174

Filing Date: February 7, 2002

Date: March 4, 2004

Page

1

of

1

Examiner: to be assigned

Group Art Unit: 1645

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's

Initials*

English

Abstract

Translation

**Readily
Available**

Enclosed

No

Enclosed

No

AR	Ke et al.; Bcl-B, a Novel Bcl-2 Family Member That Differentially Binds and Regulates Bax and Bak; The Journal of Biological Chemistry, Vol. 276, No. 16; 04/2001; p. 12481-12484
----	---

BR	Aouacheria et al.; Nrh, a human homologue of Nr-13 associates with Bcl-Xs and is an inhibitor of apoptosis; Oncogene, Vol. 20; 2001; p. 5846-5855
----	---

CR	Zhang et al.; Bcl2-L-10, a novel anti-apoptotic member of the Bcl-2 family, blocks apoptosis in the mitochondria death pathway but not in the death receptor pathway; Human Molecular Genetics, Vol. 10, No. 21; 2001; p. 2329-2339
----	---

DR	Bouillet et al., BH3-only proteins – evolutionarily conserved pro-apoptotic Bcl-2 family members essential for initiating programmed cell death; Journal of Cell Science, Vol. 115; 2002; p. 1567-1574
----	--

ER

FR

GR

HR	
----	--

IR

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.